ERC Society for Endocrinology Archive
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Accepted Preprint first posted online on 23 December 2008

Endocrine-Related Cancer 2009;16:201.

DOI: 10.1677/ERC-08-0119
Copyright © 2008 by the Society for Endocrinology.
This Article
Right arrow Accepted manuscript (PDF)
Right arrow All Versions of this Article:
ERC-08-0119v1
16/1/201    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perrino, M.
Right arrow Articles by Fugazzola, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perrino, M.
Right arrow Articles by Fugazzola, L.

RESEARCH

Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers ≤2cm

Michela Perrino, Guia Vannucchi, Leonardo Vicentini, Gianmaria Cantoni, Davide Dazzi, Carla Colombo, Marcello Rodari, Arturo Chiti, Paolo Beck-Peccoz and Laura Fugazzola

M Perrino, Department of Medical Sciences, University of Milan, Endocrine Unit Fondazione Policlinico IRCCS, Milan, Italy
G Vannucchi, Department of Medical Sciences, University of Milan, Endocrine Unit Fondazione Policlinico IRCCS, Milan, Italy
L Vicentini, Fondazione Policlinico IRCCS, Endocrine Surgery Unit, Milan, Italy
G Cantoni, Fondazione Policlinico IRCCS, Endocrine Surgery Unit, Milan, Italy
D Dazzi, Department of Medical Sciences, University of Milan, Endocrine Unit Fondazione Policlinico IRCCS, Milan, Italy
C Colombo, Department of Medical Sciences, University of Milan, Endocrine Unit Fondazione Policlinico IRCCS, Milan, Italy
M Rodari, Istituto Clinico Humanitas IRCCS, Nuclear Medicine Unit, Milan, Italy
A Chiti, Istituto Clinico Humanitas IRCCS, Nuclear Medicine Unit, Milan, Italy
P Beck-Peccoz, Department of Medical Sciences, University of Milan, Endocrine Unit Fondazione Policlinico IRCCS, Milan, Italy
L Fugazzola, Department of Medical Sciences, University of Milan, Endocrine Unit Fondazione Policlinico IRCCS, Milan, Italy

Correspondence: Laura Fugazzola, Email: l.fugazzola{at}policlinico.mi.it

Abstract

The incidence of papillary thyroid cancer (PTC) is rapidly growing, being the recorded increase mainly related to tumors ≤2 cm. The re-classification of tumors >1 and ≤2cm limited to the thyroid from the T2 to the T1 category, triggered some concerns about their best management. In order to identify possible predictors of disease outcome, several clinico-pathological features were analyzed by uni- and multivariate analyses in a retrospective consecutive series of 251 PTCs ≤2 cm. Moreover, since the 37% of cases were submitted to prophylactic central compartment node dissection (CLND, VI-VII levels) and radioiodine ablation was performed only when the tumor had an extrathyroidal extension, the impact of these therapeutic tools on the final outcome was evaluated. Among all outcome predictors analyzed, only lymph-node metastases and extracapsular invasion were strongly associated with persistence/recurrence. It is worth noting that neither age, nor tumor size were significant indicators of the outcome. Interestingly, as far as the therapeutic interventions are concerned, CLND was strongly associated with remission, whereas radioiodine ablation did not influence the outcome. In conclusion, present results confirm the prognostic influence of node metastases and extrathyroidal invasion indicating the need for aggressive treatment in tumors extending beyond the capsule. On the contrary, all pT1N0 tumors, regardless of the diameter, the number of intrathyroidal foci and the age can be effectively treated only by surgery. The major impact of prophylactic CLND on prognosis, suggests to routinely associate it to total thyroidectomy in cases with a preoperative diagnosis of malignancy.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the Society for Endocrinology.